GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » Total Liabilities

Lipella Pharmaceuticals (Lipella Pharmaceuticals) Total Liabilities : $0.58 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals Total Liabilities?

Lipella Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was $0.58 Mil.

Lipella Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 ($0.62 Mil) to Dec. 2023 ($0.43 Mil) but then increased from Dec. 2023 ($0.43 Mil) to Mar. 2024 ($0.58 Mil).

Lipella Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 ($0.59 Mil) to Dec. 2022 ($1.28 Mil) but then declined from Dec. 2022 ($1.28 Mil) to Dec. 2023 ($0.43 Mil).


Lipella Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Lipella Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals Total Liabilities Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Liabilities
0.49 0.59 1.28 0.43

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.36 0.62 0.43 0.58

Lipella Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lipella Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.385+(0.047+0.00099999999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=0.43

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=3.577-3.144
=0.43

Lipella Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.552+(0.024+-9.0205620750794E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=0.58

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=3.137-2.561
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipella Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipella Pharmaceuticals (Lipella Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.
Executives
Lori Birder director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman director, 10 percent owner, officer: See Remarks C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston officer: Chief Financial Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor director, 10 percent owner, officer: Chief Medical Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208